PHARMX TECHNOLOGIES LIMITED — Interim / Quarterly Report 2022

Dec 7, 2021

==> picture [231 x 270] intentionally omitted <==

==> picture [274 x 196] intentionally omitted <==

Corum Group Limited Trading Update Wednesday, December 8, 2021

==> picture [223 x 122] intentionally omitted <==

Important Notice & Disclaimer

This presentation has been prepared by Corum Group Limited (COO or the Company or Corum). It should not be considered as an offer or invitation to subscribe for, or purchase any shares in COO, or as an inducement to purchase any shares in COO.No agreement to subscribe for securities in COO will be entered into on the basis of this presentation or any information, opinions or conclusions expressed in the course of this presentation.

This presentation is not a prospectus, product disclosure document, or other offering document under Australian law or under the law of any other jurisdiction. It has been prepared for information purposes only. This presentation contains general summary information and does not take into account the investment objectives, financial situation and particular needs of an individual investor. It is not a financial product advice and the Company is not licensed to, and does not provide, financial advice.

This presentation may contain forward-looking statements which are identified by words such as ‘may’, ‘could’, ‘believes’, ‘estimates’, ‘targets’, ‘expects’, or ‘intends’ and other similar words that involve risks and uncertainties. These statements are based on an assessment of past and present economic and operating conditions, and on a number of assumptions regarding future events and actions that, as at the date of this presentation, are expected to take place.Such forward-looking statements do not guarantee of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors many of which are beyond the control of the Company, its Directors and management.

assurance that the results, performance or achievements expressed or implied by the forward-looking statements contained in this document will actually occur or that the assumptions on which those statements are based are exhaustive or will prove to be correct beyond the date of its making.

Readers are cautioned not to place undue reliance on these forward-looking statements. Except to the extent required by law, the Company has no intention to update or revise forward-looking statements, or to publish prospective financial information in the future, regardless of whether new information, future events or any other factors affect the information contained in this presentation.

Readers should make their own independent assessment of the information and take their own independent professional advice in relation to the information and any proposed action to be taken on the basis of the information. To the maximum extent permitted by law, the Company and its professional advisors and their related bodies corporate, affiliates an each of their respective directors, officers, management, employees, advisers and agents and any other person involved in the preparation of this presentation disclaim all liability and responsibility (including without limitation and liability arising from fault or negligence) for any direct or indirect loss or damage which may arise or be suffered through use of or reliance on anything contained in, or omitted from, this presentation. Neither the Company nor its advisors have any responsibility or obligation to update this presentation or inform the reader of any matter arising or coming to their notice after the date of this presentation document which may affect any matter referred to in the presentation.

Although the Company believes that the expectations reflected in the forwardlooking statements included in this presentation are reasonable, none of the Company, its Directors or officers can give, or gives, any

==> picture [144 x 46] intentionally omitted <==

==> picture [99 x 97] intentionally omitted <==

2

FY22 Q1 Key Highlights Creating Positive Momentum

Financials

• Total group revenue for the quarter(1) of $3.3m up 7% on pcp.

• Health Services revenue of $3.0m for the quarter(1), up 11% on pcp, primarily attributable

to PharmX.

• Real Estate eCommerce decline in line with expectations with revenue for the quarter of

$0.3m(1), down 20% on pcp.

• Closing cash balance as of 26 October 2021 of $7.5m ( up 16% since 30 June 2021)

==> picture [464 x 17] intentionally omitted <==

==> picture [144 x 46] intentionally omitted <==

==> picture [99 x 97] intentionally omitted <==

3

FY22 Q1 Key Highlights Unlocking Future Growth Opportunities

Important customer wins

• Go Vita operate 130 health and vitamin stores across Australia. Corum has entered an agreement to be their preferred operational software provider. Go Vita are the first major non-pharmacy customer for Corum. In addition, they are a large supplier to the pharmacy market and will distribute via the PharmX platform.

• Corum has extended its existing relationship with Sigma into the WholeLife branded stores. Corum has been providing head office software to Sigma’s “Discount Drug Stores” for over 10 years and our expansion into WholeLife represents another extension of a broader relationship with Sigma.

==> picture [144 x 46] intentionally omitted <==

==> picture [99 x 97] intentionally omitted <==

4

FY22 Q1 Key Highlights Developing New Growth Opportunities

CyberGuard

• Corum has launched a state-of-the-art cyber protection product for Australian pharmacies, CyberGuard.

• CyberGuard is a subscription-based service designed to prevent the increasingly prevalent ransomware attacks and ensure pharmacy patient data is protected with enterprise level technology.

==> picture [144 x 46] intentionally omitted <==

==> picture [99 x 97] intentionally omitted <==

5

FY22 Q1 Key Highlights

==> picture [48 x 41] intentionally omitted <==

PharmX Strategy

Our strategy for PharmX is threefold:

1. To grow the number of suppliers on the platform

2. To increase the utilisation rates of pharmacies as measured by connections.

3. To develop new commercial services for PharmX users, both suppliers and pharmacies.

==> picture [144 x 46] intentionally omitted <==

==> picture [99 x 97] intentionally omitted <==

4

FY22 Q1 Key Highlights

Delivering Growth and Marketplace Efficiencies

• Signed agreements with TerryWhite Chemmart, Blooms The Chemist, Alive Pharmacy Group, Good Price Pharmacy Group and Capital Chemist to drive supplier and pharmacy utilisation with the PharmX platform.

• Supplier numbers increased by 10% (a sample of new partner listed below) and connections by 12% compared to pcp.

• Industry consolidation has created a headwind - DHL

==> picture [129 x 54] intentionally omitted <==

==> picture [177 x 89] intentionally omitted <==

==> picture [129 x 65] intentionally omitted <==

==> picture [223 x 40] intentionally omitted <==

==> picture [161 x 27] intentionally omitted <==

==> picture [78 x 75] intentionally omitted <==

==> picture [118 x 76] intentionally omitted <==

==> picture [178 x 60] intentionally omitted <==

==> picture [223 x 97] intentionally omitted <==

==> picture [7 x 9] intentionally omitted <==

----- Start of picture text -----

6
----- End of picture text -----

FY22 Q1 Key Highlights Develop New Commercial Services

DataMesh

• Corum has entered into an agreement with DataMesh Group to develop payment capabilities across our customer network.

• DataMesh Group provide a range of services including the provision of streamlined, low cost and flexible integrated payment terminal solutions.

Marketplace

• To assist with the of smaller on the PharmX we have a growth suppliers platform developed

• marketplace platform.

==> picture [636 x 89] intentionally omitted <==

----- Start of picture text -----

7
----- End of picture text -----

FY22 Q1 Key Highlights Augmenting Organic Growth Through Targeted Acquisitions

TMT Partners

• TMT Partners have been engaged as corporate advisors to actively seek merger and

• acquisition opportunities.

==> picture [636 x 324] intentionally omitted <==

----- Start of picture text -----

8
----- End of picture text -----

FY22 Q1 Key Highlights

SUMMARY

Financial momentum & uplift in cash at bank

==> picture [45 x 42] intentionally omitted <==

Total Group revenue for the quarter up 7% pcp.

Health Services revenue up 11% pcp.

Closing cash balance, as at 26 Oct 2021, $7.5m (up 16% since 30 June 2021).

==> picture [144 x 46] intentionally omitted <==

Unlocking Future Growth Opportunities

==> picture [51 x 44] intentionally omitted <==

Signed Go Vita, 130 health and vitamin stores, our first major non-pharmacy customer. Preferred Head Office supplier for Pharmacy Essentials. Extended

relationship with Sigma with the WholeLife brand.

Launched CyberGuard, a subscription-based service to protect pharmacy data.

Delivering Growth and Marketplace Efficiencies

Increased supplier numbers on PharmX by 10% and connections by 12% compared to pcp.

Signed agreements with a range of retail groups to drive PharmX utilisation including TerryWhite Chemmart, Blooms The Chemist, Alive Pharmacy Group, Good Price Pharmacy Group and Capital Chemist.

Augmenting Organic Growth Through Targeted Acquisition and Partnerships

Engaged TMT Partners to actively seek merger and acquisition opportunities.

Entered into an agreement with DataMesh to develop payment capabilities across our customer network.

==> picture [99 x 97] intentionally omitted <==

9

==> picture [162 x 189] intentionally omitted <==

Questions?

==> picture [291 x 134] intentionally omitted <==

==> picture [231 x 270] intentionally omitted <==

Corum Group Limited Contact: Investor.Relations@corum.com.au

==> picture [198 x 141] intentionally omitted <==

==> picture [58 x 58] intentionally omitted <==